FARMINGTON, Conn. (PRWEB) February 04, 2019
Torigen Pharmaceuticals, a company developing personalized cancer immunotherapies for the veterinary market, announced today the completion of a $3.1 million Series A financing round led by Connecticut Innovations, which included the conversion of outstanding convertible debt and interest. The company will use these funds to continue to innovate through its research and development platform, expand its customer support team, and continue to provide Torigen’s U.S. experimental cancer vaccine to the veterinary community.
Each year in the United States, over 8 million companion animals are diagnosed with cancer. Torigen is focused on providing innovative and affordable cancer therapies to pet owners.
“Cancer rates in pets are increasing, and existing treatment options are too expensive for many pet owners,” said Torigen’s CEO, Ashley Kalinauskas. “The capital we have obtained from great investment partners including Connecticut Innovations, the UConn Innovation Fund, SoGal Ventures, The Fund and prominent angel investors will position our company for growth and success.”
Forward-thinking veterinarians throughout the United States are currently using Torigen’s experimental companion animal cancer treatment, which utilizes a portion of the patient’s own tumor that is sent to Torigen’s laboratory for creation of a personalized vaccine.
“For the millennial generation, pets are as integral to the family unit as human children,” said SoGal Ventures investor Elizabeth Galbut. “We’re certain that the next generation of pet owners will demand a more affordable, convenient and technologically advanced treatment option for their dog or cat battling cancer. Torigen is leading the way – with personalized treatments that are backed by groundbreaking science and accessibly priced so more families can afford to provide their pets with desperately needed treatment.”
About Torigen Pharmaceuticals Inc.
Torigen Pharmaceuticals Inc. is focused on delivering affordable companion animal immuno-oncology products. Its initial patented product line utilizes a portion of the pet-patient’s tumor to create a personalized cancer vaccine. With over 10 years of supporting pre-clinical publications, the Torigen team is focused on developing innovative veterinary cancer biologics that allow for the body to recognize foreign tumor-associated antigens and facilitate the reversal of immune senescence. For more information, please visit http://www.torigen.com.